AIM-Harvard/TrialPanorama-filtered huggingface dataset:
Trial: 15470334
Drug: Flurbiprofen (65
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Flurbiprofen (65 mg)
Trial: 12042232
Drug: Nefazodone 400-600
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Nefazodone 400-600 mg/day
Trial: 1688499
Drug: Intravenous gammaglobulin
RxNorm normalized name: Human gammaglobulin
DrugBank: Human immunoglobulin G (DB00028)
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Intravenous gammaglobulin (IV‐IgG) at a dose of 400 mg/kg for 5 days
Trial: 31383945
Drug: Surface measurement
RxNorm normalized name: hepatitis B surface antigen vaccine Injection [Recombivax]
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Surface measurement (SM) method among BW < 1000 g
Trial: 31383945
Drug: Birth weight
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Birth weight (BW) method among BW < 1000 g
Trial: 31694493
Drug: Normal-weight central
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Normal-weight central obesity measured by subcutaneous fat thickness
Trial: 27522981
Drug: Autologous platelet
RxNorm normalized name: AUTOLOGOUS PLATELET RICH PLASMA
DrugBank: Platelet Rich Plasma (DB19295)
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Autologous platelet gel
Trial: 27522981
Drug: Antiseptic ointment
RxNorm normalized name: Listerine Antiseptic
DrugBank: Menthol (DB14123)
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Antiseptic ointment dressing
Trial: 25844614
Drug: HSP infusion
RxNorm normalized name: Duo Fusion
DrugBank: Magnesium hydroxide (DB09104)
FDA approved: yes
EMA approved: no
PMDA approved: no
Description: HSP infusion head
Trial: 23637110
Drug: Joint crisis
RxNorm normalized name: ActivOn Joint & Muscle
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Joint crisis plan in addition to treatment as usual (TAU)
Trial: 22922860
Drug: Oral iron
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Oral iron (iron fumarate)
Trial: 15724865
Drug: Magnesium therapy
RxNorm normalized name: Magnesium
DrugBank: Magnesium (DB14513)
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Magnesium therapy (Magne B(6)R, Sanofi‐Synthelabo)
Trial: 7485860
Drug: Topical ciprofloxacin
RxNorm normalized name: Ciprofloxacin
DrugBank: Ciprofloxacin (DB00537)
FDA approved: yes
EMA approved: no
PMDA approved: no
Description: Topical ciprofloxacin (0.3%)
Trial: 8924287
Drug: Topical gentamicin
RxNorm normalized name: gentamicin Topical Ointment
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Topical gentamicin (0.3%)
Trial: 2404660
Drug: Combined pharmacotherapy
RxNorm normalized name: combinations
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Combined pharmacotherapy plus cognitive-behavioral psychotherapy
Trial: 7197978
Drug: Amezinium 10
RxNorm normalized name: amezinium 10 MG
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Amezinium 10 mg i.v.
Trial: 7197978
Drug: Amezinium (various
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Amezinium (various p.o. doses)
Trial: 7197978
Drug: Norfenefrine 10
RxNorm normalized name: norfenefrine 10 MG
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Norfenefrine 10 mg i.m. and 40 mg p.o.
Trial: 7197978
Drug: Dihydroergotamine 1
RxNorm normalized name: DIHYDROERGOTAMINE 1MG/ML INJ AMP 1ML
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Dihydroergotamine 1 mg i.m. and 4 mg p.o.
Trial: 31699131
Drug: Combined group
RxNorm normalized name: Streptococcus viridans group
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Combined group (15 mg/kg IV-TXA + 2 g topical TXA)
Trial: 31699131
Drug: IV group
RxNorm normalized name: meningococcal group B vaccine Prefilled Syringe [Trumenba]
FDA approved: no
EMA approved: no
PMDA approved: no
Description: IV group (15 mg/kg IV-TXA)
Trial: 28081719
Drug: Antibiotic Prophylaxis
RxNorm normalized name: STONE PROPHYLAXIS
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Antibiotic Prophylaxis (AP) continued
Trial: 28081719
Drug: Antibiotic Prophylaxis
RxNorm normalized name: STONE PROPHYLAXIS
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Antibiotic Prophylaxis (AP) stopped
Trial: 17150319
Drug: Chios mastic
RxNorm normalized name: Thymus mastichina flowering top oil
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Chios mastic powder (5g daily, high-dose group)
Trial: 17150319
Drug: Chios mastic
RxNorm normalized name: Thymus mastichina flowering top oil
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Chios mastic solution (low-dose group)
Trial: 15522140
Drug: Dried garlic
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Dried garlic powder tablets (10.8 mg alliin/d, corresponding to about three garlic cloves)
Trial: 29987109
Drug: Sitagliptin 100
RxNorm normalized name: SITagliptin 100 MG
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Sitagliptin 100 mg/d plus valsartan 160 mg/d
Trial: 25019209
Drug: 300 mg
RxNorm normalized name: rutin 300 MG
FDA approved: no
EMA approved: no
PMDA approved: no
Description: 300 mg of RSV
Trial: 11063393
Drug: Chlorhexidine (CHX)
RxNorm normalized name: chlorhexidine gluconate Topical Solution [CHX Plus]
DrugBank: Chlorhexidine (DB00878)
FDA approved: yes
EMA approved: no
PMDA approved: no
Description: Chlorhexidine (CHX) mouthwash, performed twice daily for 3 weeks
Trial: 11063393
Drug: Amine fluoride/stannous
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Amine fluoride/stannous fluoride (AmF/SnF2) mouthwash, performed twice daily for 3 weeks
Trial: 8832997
Drug: Zolpidem 5
RxNorm normalized name: zolpidem 5 mg oral tablet
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Zolpidem 5 mg, 10 mg, or 15 mg at bedtime
Trial: 25134378
Drug: High serum
FDA approved: no
EMA approved: no
PMDA approved: no
Description: High serum procalcitonin (> 0.5 ng/mL)
Trial: 25134378
Drug: Procalcitonin >
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Procalcitonin > 1.0 ng/mL
Trial: 21068427
Drug: Bihemispheric transcranial
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Bihemispheric transcranial direct current stimulation (tDCS) with simultaneous physical/occupational therapy
Trial: 21068427
Drug: Sham stimulation
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Sham stimulation with simultaneous physical/occupational therapy
Trial: 17694946
Drug: Cemented, implant-retained
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Cemented, implant-retained fixed superstructures in periodontally healthy patients
Trial: 9466021
Drug: Propofol infusion
RxNorm normalized name: Propofol
DrugBank: Propofol (DB00818)
FDA approved: yes
EMA approved: no
PMDA approved: no
Description: Propofol infusion preceded by normal saline (group P, n = 12)
Trial: 7629003
Drug: Uni-Dur (q24h
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Uni-Dur (q24h extended-release theophylline)
Trial: 7629003
Drug: Theo-Dur (q12h
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Theo-Dur (q12h extended-release theophylline)
Trial: 2380943
Drug: Prescription information
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Prescription information leaflets
Trial: 2380943
Drug: No prescription
FDA approved: no
EMA approved: no
PMDA approved: no
Description: No prescription information leaflets (Control)
Trial: 366143
Drug: 50 mg
RxNorm normalized name: talc 50 MG
FDA approved: no
EMA approved: no
PMDA approved: no
Description: 50 mg levamisole once weekly
Trial: 366143
Drug: 150 mg
RxNorm normalized name: pectin 150 MG
FDA approved: no
EMA approved: no
PMDA approved: no
Description: 150 mg levamisole on 3 or 7 consecutive days
Trial: 23864786
Drug: Amitriptyline (12.5
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Amitriptyline (12.5 mg tid)
Trial: 19176454
Drug: Sequential chemotherapy
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Sequential chemotherapy followed by radiotherapy (70 Gy total) after two cycles of cisplatin and 5‐fluorouracil, with a 50% or more reduction in primary tumor size.
Trial: 19176454
Drug: Alternating chemotherapy
RxNorm normalized name: yellow fever virus strain 17D-204 live antigen
DrugBank: Yellow fever vaccine (DB10805)
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Alternating chemotherapy and radiotherapy (60 Gy total) with four cycles of cisplatin and 5‐fluorouracil alternated with radiotherapy (20 Gy during the three 2‐week intervals).
Trial: 17245803
Drug: Anthrax vaccine
RxNorm normalized name: ANTHRAX VACCINE
DrugBank: Anthrax vaccine (DB11003)
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Anthrax vaccine
Trial: 15792325
Drug: Iowa Case
RxNorm normalized name: influenza B virus B/Iowa/06/2017 antigen
DrugBank: Influenza B virus B/Iowa/06/2017 antigen (MDCK cell derived, propiolactone inactivated) (DB15508)
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Iowa Case Management Project (ICMP) for Rural Drug Abuse
Trial: 12368673
Drug: GH plus
RxNorm normalized name: Pediacare Cough Plus Cold
FDA approved: no
EMA approved: no
PMDA approved: no
Description: GH plus propranolol therapy
Trial: 12368673
Drug: Combination GH
RxNorm normalized name: combinations
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Combination GH plus propranolol therapy
Trial: 20726913
Drug: Intracanal medication
RxNorm normalized name: dexamethasone
DrugBank: Dexamethasone acetate (DB14649)
FDA approved: yes
EMA approved: no
PMDA approved: yes
Description: Intracanal medication with calcium hydroxide [Ca(OH)(2)] for 1 week (n=35)
Trial: 15751152
Drug: Pegvisomant (10
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Pegvisomant (10 mg to 20 mg/day subcutaneously)
Trial: 8777660
Drug: 1 ml
RxNorm normalized name: ethanol 1 ML/ML
FDA approved: no
EMA approved: no
PMDA approved: no
Description: 1 ml of 25% sucrose solution
Trial: 1920344
Drug: Nicardipine 60
RxNorm normalized name: niCARdipine 60 mg oral capsule, extended release
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Nicardipine 60 or 90 mg/day
Trial: 1920344
Drug: Propranolol 90-240
RxNorm normalized name: propranolol hydrochloride 90 MG
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Propranolol 90-240 mg/day
Trial: 6136290
Drug: Diazepam (0.15
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Diazepam (0.15 mg kg‐1)
Trial: 26868210
Drug: Anti-asthma drug
RxNorm normalized name: Anti Bac
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Anti-asthma drug prescription
Trial: 26868210
Drug: Anti-asthmatic medication
RxNorm normalized name: pramoxine hydrochloride Medicated Pad [Scalpicin Anti-Itch]
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Anti-asthmatic medication use in Viborg vascular trial
Trial: 12388959
Drug: Acetaminophen 650
RxNorm normalized name: acetaminophen 650 MG
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Acetaminophen 650 mg every 4 hours
Trial: 23576267
Drug: Acupuncture treatment
RxNorm normalized name: Hongo Killer Treatment
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Acupuncture treatment twice weekly for 4 weeks
Trial: 7770313
Drug: Desipramine (25
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Desipramine (25 mg four times daily)
Trial: 7770313
Drug: Clonidine (0.05
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Clonidine (0.05 mg four times daily)
Trial: 8752186
Drug: Lovastatin 40
RxNorm normalized name: lovastatin 40 MG
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Lovastatin 40 mg once daily
Trial: 8628597
Drug: Lovastatin (all
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Lovastatin (all doses)
Trial: 22872323
Drug: 30 ml
RxNorm normalized name: Vial M/T 30 mL
FDA approved: no
EMA approved: no
PMDA approved: no
Description: 30 ml simple olive oil (OO)
Trial: 22872323
Drug: 30 ml
RxNorm normalized name: Vial M/T 30 mL
FDA approved: no
EMA approved: no
PMDA approved: no
Description: 30 ml EGCG-supplemented olive oil (OO)
Trial: 19926959
Drug: Enhanced labor
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Enhanced labor ward-based services for PMTCT (opt-in HIV testing and NVP administration)
Trial: 10235351
Drug: Prophylactic tropisetron
RxNorm normalized name: tropisetron
DrugBank: Tropisetron (DB11699)
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Prophylactic tropisetron 5 mg orally before anesthesia
Trial: 27451818
Drug: DOTS Category
RxNorm normalized name: D3 Dots
FDA approved: no
EMA approved: no
PMDA approved: no
Description: DOTS Category I treatment plus prednisolone 1mg/kg for first 4 weeks, then tapered down
Trial: 27451818
Drug: DOTS Category
RxNorm normalized name: D3 Dots
FDA approved: no
EMA approved: no
PMDA approved: no
Description: DOTS Category I treatment plus placebo
Trial: 27451818
Drug: DOTS Category
RxNorm normalized name: D3 Dots
FDA approved: no
EMA approved: no
PMDA approved: no
Description: DOTS Category I treatment plus prednisolone
Trial: 24213955
Drug: 3 hours
RxNorm normalized name: nitroglycerin 0.3 MG/HR
FDA approved: no
EMA approved: no
PMDA approved: no
Description: 3 hours of rehabilitation treatment including aerobic exercise for 28 days (Group 1)
Trial: 24213955
Drug: Not therapy
RxNorm normalized name: Monistat Simple Therapy
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Not therapy (control; Group 2)
Trial: 20090328
Drug: Resin infiltration
RxNorm normalized name: Benzoin resin
DrugBank: Benzoin resin (DB11222)
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Resin infiltration (etched for 5 s with 37% H(3)PO(4) and infiltrated twice for 60 s)
Trial: 20090328
Drug: Untreated control
RxNorm normalized name: benzoyl peroxide
DrugBank: Benzoyl peroxide (DB09096)
FDA approved: yes
EMA approved: no
PMDA approved: no
Description: Untreated control (no treatment applied)
Trial: 16002181
Drug: Sustained-release chlorhexidine
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Sustained-release chlorhexidine dressing
Trial: 11974977
Drug: Pericranial injection
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Pericranial injection of 10 x 20 MU DYSPORT
Trial: 10759934
Drug: Injection of
RxNorm normalized name: purified protein derivative of tuberculin Injectable Solution [Aplisol]
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Injection of isotonic saline (placebo)
Trial: 6971940
Drug: Anti-inflammatory analgesics
RxNorm normalized name: NON-STEROIDAL ANTI-INFLAMMATORY ANALGESICS
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Anti-inflammatory analgesics
Trial: 26964827
Drug: Nebulized magnesium
RxNorm normalized name: Hydra-Neb
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Nebulized magnesium sulfate (3 ml of 260 mmol/L solution every 20 to 60 minutes)
Trial: 20564607
Drug: Alverine citrate
RxNorm normalized name: alverine citrate
DrugBank: Alverine (DB01616)
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Alverine citrate 120 mg capsule
Trial: 17013645
Drug: Zoledronic acid
RxNorm normalized name: Zoledronic Acid
DrugBank: Zoledronic acid (DB00399)
FDA approved: yes
EMA approved: yes
PMDA approved: no
Description: Zoledronic acid (1 mg intravenously every 3 months for a total of four doses)
Trial: 16119667
Drug: Assessment of
RxNorm normalized name: OIL OF CAMPHOR
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Assessment of physical state after treatment
Trial: 11124916
Drug: Oral vitamin
RxNorm normalized name: vitamin A Oral Tablet
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Oral vitamin A supplementation (5000 IU/day)
Trial: 9701528
Drug: Trimebutine (50
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Trimebutine (50 mg intravenous injection)
Trial: 8029677
Drug: Preoperative intravenous
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Preoperative intravenous cholangiography
Trial: 8029677
Drug: No preoperative
FDA approved: no
EMA approved: no
PMDA approved: no
Description: No preoperative intravenous cholangiography
Trial: 30875348
Drug: Lapatinib 1000
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Lapatinib 1000 mg daily with eribulin 1.23 mg/m (split-dose arm) days 1+8 every 21 days
Trial: 30875348
Drug: Eribulin 1.76
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Eribulin 1.76 mg/m (3-weekly arm) day 1 every 21 days
Trial: 30695420
Drug: Basic treatment
RxNorm normalized name: Basic Fuchsin
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Basic treatment of Western medicine (WM) and retention enema of Chinese medicine (CM)
Trial: 21624541
Drug: Fish oil
RxNorm normalized name: Fish oil
DrugBank: Fish oil (DB13961)
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Fish oil supplementation (6 g/day for a mean of 40 ± 12 days)
Trial: 16682588
Drug: Simvastatin (daily
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Simvastatin (daily administration for 7 days)
Trial: 16682588
Drug: Simvastatin (90
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Simvastatin (90 minutes after administration)
Trial: 16682588
Drug: Simvastatin (90
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Simvastatin (90 minutes and 7 days after administration)
Trial: 11406520
Drug: D2E7 (anti-TNF
FDA approved: no
EMA approved: no
PMDA approved: no
Description: D2E7 (anti-TNF monoclonal antibody)
Trial: 7810814
Drug: Ointment containing
RxNorm normalized name: fish oil (containing omega-3 acids) Injection [Omegaven]
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Ointment containing two antibiotics
Trial: 7810814
Drug: Ointment containing
RxNorm normalized name: fish oil (containing omega-3 acids) Injection [Omegaven]
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Ointment containing one antibiotic plus hydrocortisone
Trial: 26571890
Drug: Combined therapy
RxNorm normalized name: REGN10933+REGN10987 combination therapy
DrugBank: Anti-SARS-CoV-2 REGN-COV2 (DB15691)
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Combined therapy of auricular point sticking and Xiaopijian
Trial: 24260195
Drug: FMP2.1/AS02A vaccine
FDA approved: no
EMA approved: no
PMDA approved: no
Description: FMP2.1/AS02A vaccine
Trial: 1689740
Drug: Finasteride (doses
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Finasteride (doses of 0.2-80 mg)
Trial: 30400934
Drug: 3-month malaria
RxNorm normalized name: PLASMODIUM MALARIAE
FDA approved: no
EMA approved: no
PMDA approved: no
Description: 3-month malaria chemoprevention (PMC) with monthly 3-day treatment courses of dihydroartemisinin-piperaquine at 2, 6, and 10 weeks after discharge
Trial: 30400934
Drug: Standard in-hospital
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Standard in-hospital care plus a single 3-day treatment course with artemether-lumefantrine at discharge
Trial: 24799520
Drug: Initial antiepileptic
RxNorm normalized name: brigatinib
DrugBank: Brigatinib (DB12267)
FDA approved: yes
EMA approved: yes
PMDA approved: yes
Description: Initial antiepileptic treatment
Trial: 24799520
Drug: EEG characteristics
FDA approved: no
EMA approved: no
PMDA approved: no
Description: EEG characteristics prior to treatment
Trial: 22381025
Drug: Encapsulated supplement
RxNorm normalized name: liposomal encapsulated paclitaxel
DrugBank: Paclitaxel (DB01229)
FDA approved: yes
EMA approved: yes
PMDA approved: yes
Description: Encapsulated supplement of fruit and vegetable juice concentrate (FVJC) for 6 months
Trial: 18046109
Drug: Irbesartan/HCTZ 300/25
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Irbesartan/HCTZ 300/25 mg once daily for 7 to 8 weeks
Trial: 10549460
Drug: Propofol infusion,
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Propofol infusion, 1 mg kg‐1 min‐1 intravenous for 2 min, followed by propofol infusion, 200 micrograms kg‐1 min‐1
Trial: 10549460
Drug: Fentanyl bolus,
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Fentanyl bolus, 1 microgram kg‐1 intravenous + propofol infusion as in Group P
Trial: 10549460
Drug: Fentanyl bolus,
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Fentanyl bolus, 2 micrograms kg‐1 intravenous + propofol infusion as in Group P
Trial: 10549460
Drug: Fentanyl bolus,
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Fentanyl bolus, 3 micrograms kg‐1 intravenous + propofol infusion as in Group P
Trial: 153862
Drug: Benzoyl peroxide
RxNorm normalized name: Benzoyl Peroxide
DrugBank: Benzoyl peroxide (DB09096)
FDA approved: yes
EMA approved: no
PMDA approved: no
Description: Benzoyl peroxide treatment for 4 weeks
Trial: 153862
Drug: Benzoyl peroxide
RxNorm normalized name: Benzoyl Peroxide
DrugBank: Benzoyl peroxide (DB09096)
FDA approved: yes
EMA approved: no
PMDA approved: no
Description: Benzoyl peroxide treatment for 1 week
Trial: 30987164
Drug: Hydromorphone treatment
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Hydromorphone treatment
Trial: 15370684
Drug: 4% ethanol
FDA approved: no
EMA approved: no
PMDA approved: no
Description: 4% ethanol solution
Trial: 15370684
Drug: 10% ethanol
FDA approved: no
EMA approved: no
PMDA approved: no
Description: 10% ethanol solution
Trial: 15370684
Drug: 40% ethanol
FDA approved: no
EMA approved: no
PMDA approved: no
Description: 40% ethanol solution
Trial: 15370684
Drug: Water (500
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Water (500 mL)
Trial: 11867933
Drug: Etidronate (EHDP)
RxNorm normalized name: etidronate
DrugBank: Etidronic acid (DB01077)
FDA approved: yes
EMA approved: no
PMDA approved: no
Description: Etidronate (EHDP) therapy
Trial: 10221416
Drug: Ciprofloxacin 500
RxNorm normalized name: ciprofloxacin 500 MG
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Ciprofloxacin 500 mg once daily (q.i.d.)
Trial: 10221416
Drug: Ciprofloxacin 250
RxNorm normalized name: ciprofloxacin 250 MG
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Ciprofloxacin 250 mg twice daily (b.i.d.)
Trial: 8657840
Drug: lorazepam (2
FDA approved: no
EMA approved: no
PMDA approved: no
Description: lorazepam (2 mg PO)
Trial: 8657840
Drug: scopolamine (0.5
FDA approved: no
EMA approved: no
PMDA approved: no
Description: scopolamine (0.5 mg IV)
Trial: 8657840
Drug: glycopyrrolate (0.2
FDA approved: no
EMA approved: no
PMDA approved: no
Description: glycopyrrolate (0.2 mg IV)
Trial: 6772045
Drug: Total parenteral
RxNorm normalized name: TPN - total parenteral nutrition
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Total parenteral nutrition preoperatively (group 1)
Trial: 6772045
Drug: Total parenteral
RxNorm normalized name: TPN - total parenteral nutrition
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Total parenteral nutrition postoperatively (group 2)
Trial: 31538372
Drug: Osmotic‐Release Oral
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Osmotic‐Release Oral System Methylphenidate (OROS‐MPH)
Trial: 30387461
Drug: Triamcinolone ointment
RxNorm normalized name: Triamcinolone
DrugBank: Triamcinolone (DB00620)
FDA approved: yes
EMA approved: no
PMDA approved: no
Description: Triamcinolone ointment
Trial: 30387461
Drug: Water-based gel
RxNorm normalized name: benzoyl peroxide
DrugBank: Benzoyl peroxide (DB09096)
FDA approved: yes
EMA approved: no
PMDA approved: no
Description: Water-based gel (Control)
Trial: 12324291
Drug: L-796568 (375
FDA approved: no
EMA approved: no
PMDA approved: no
Description: L-796568 (375 mg/d)